Wellington Management Group LLP Sells 166,792 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Wellington Management Group LLP trimmed its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 3.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,431,920 shares of the company’s stock after selling 166,792 shares during the quarter. Wellington Management Group LLP owned approximately 4.09% of Vaxcyte worth $278,325,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Goldman Sachs Group Inc. raised its position in Vaxcyte by 12.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock valued at $30,214,000 after purchasing an additional 52,005 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in Vaxcyte by 54.5% during the 4th quarter. Eventide Asset Management LLC now owns 607,206 shares of the company’s stock worth $38,133,000 after buying an additional 214,206 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in Vaxcyte by 12.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 267,594 shares of the company’s stock worth $16,805,000 after purchasing an additional 29,462 shares during the period. Vestal Point Capital LP bought a new stake in Vaxcyte during the 4th quarter worth about $32,970,000. Finally, Capital Research Global Investors lifted its position in Vaxcyte by 2.3% during the 4th quarter. Capital Research Global Investors now owns 3,440,107 shares of the company’s stock valued at $216,039,000 after purchasing an additional 75,980 shares during the period. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on PCVX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Thursday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $95.00 price target on shares of Vaxcyte in a research report on Thursday, May 9th.

Insider Buying and Selling at Vaxcyte

In other news, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $66.93, for a total transaction of $1,003,950.00. Following the completion of the sale, the chief executive officer now owns 477,847 shares of the company’s stock, valued at $31,982,299.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $72.06, for a total value of $120,124.02. Following the sale, the senior vice president now owns 31,161 shares of the company’s stock, valued at approximately $2,245,461.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00. Following the transaction, the chief executive officer now directly owns 477,847 shares of the company’s stock, valued at approximately $31,982,299.71. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 86,483 shares of company stock valued at $5,917,483. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Price Performance

Shares of PCVX stock opened at $71.88 on Tuesday. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $82.04. The firm has a fifty day moving average of $67.40 and a 200-day moving average of $66.83.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.28. Equities analysts predict that Vaxcyte, Inc. will post -3.96 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.